Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jmb.2021.167155 http://scihub22266oqcxt.onion/10.1016/j.jmb.2021.167155 34273397!8277955!34273397     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Mol+Biol 2021 ; 433 (18): 167155 Nephropedia Template TP {{tp|p=34273397|t=2021. Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies |pdf=|usr=}}{{34273397}} gab.com Text Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies JO: J Mol Biol http://www.kidney.de/pget.php?&tw=1&pmid=34273397 #FOAvip The ongoing massive vaccination and the development of effective intervention offer the long-awaited hope to end the global rage of the COVID-19 pandemic. However, the rapidly growing SARS-CoV-2 variants might compromise existing vaccines and monoclonal antibody (mAb) therapies. Although there are valuable experimental studies about the potential threats from emerging variants, the results are limited to a handful of mutations and Eli Lilly and Regeneron mAbs. The potential threats from frequently occurring mutations on the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD) to many mAbs in clinical trials are largely unknown. We fill the gap by developing a topology-based deep learning strategy that is validated with tens of thousands of experimental data points. We analyze 796,759 genome isolates from patients to identify 606 non-degenerate RBD mutations and investigate their impacts on 16 mAbs in clinical trials. Our findings, which are highly consistent with existing experimental results about Alpha, Beta, Gamma, Delta, Epsilon, and Kappa variants shed light on potential threats of 100 most observed mutations to mAbs not only from Eli Lilly and Regeneron but also from Celltrion and Rockefeller University that are in clinical trials. We unveil, for the first time, that high-frequency mutations R346K/S, N439K, G446V, L455F, V483F/A, F486L, F490L/S, Q493L, and S494P might compromise some of mAbs in clinical trials. Our study gives rise to a general perspective about how mutations will affect current vaccines. Twit Text FOAVip Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies ????J Mol Biol http://www.kidney.de/pget.php?&tw=1&pmid=34273397 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34273397 #FOAvip English Wikipedia <ref>{{Cite pmid|34273397}}</ref> Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies #MMPMID34273397 Chen J; Gao K; Wang R; Wei GW J Mol Biol 2021[Sep]; 433 (18): 167155 PMID34273397show ga The ongoing massive vaccination and the development of effective intervention offer the long-awaited hope to end the global rage of the COVID-19 pandemic. However, the rapidly growing SARS-CoV-2 variants might compromise existing vaccines and monoclonal antibody (mAb) therapies. Although there are valuable experimental studies about the potential threats from emerging variants, the results are limited to a handful of mutations and Eli Lilly and Regeneron mAbs. The potential threats from frequently occurring mutations on the SARS-CoV-2 spike (S) protein receptor-binding domain (RBD) to many mAbs in clinical trials are largely unknown. We fill the gap by developing a topology-based deep learning strategy that is validated with tens of thousands of experimental data points. We analyze 796,759 genome isolates from patients to identify 606 non-degenerate RBD mutations and investigate their impacts on 16 mAbs in clinical trials. Our findings, which are highly consistent with existing experimental results about Alpha, Beta, Gamma, Delta, Epsilon, and Kappa variants shed light on potential threats of 100 most observed mutations to mAbs not only from Eli Lilly and Regeneron but also from Celltrion and Rockefeller University that are in clinical trials. We unveil, for the first time, that high-frequency mutations R346K/S, N439K, G446V, L455F, V483F/A, F486L, F490L/S, Q493L, and S494P might compromise some of mAbs in clinical trials. Our study gives rise to a general perspective about how mutations will affect current vaccines. |*COVID-19 Drug Treatment[MESH] |Antibodies, Monoclonal/immunology/*therapeutic use[MESH] |Antibodies, Neutralizing/immunology/therapeutic use[MESH] |Antibodies, Viral/immunology/therapeutic use[MESH] |COVID-19/immunology[MESH] |Humans[MESH] |Mutation/*drug effects/immunology[MESH] |Pandemics/prevention & control[MESH] |Protein Binding/immunology[MESH] |SARS-CoV-2/*drug effects/immunology[MESH]Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Ther(epmc).pdf DeepDyve Pubget Overpricing